Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment

Annals of Occupational Hygiene

Volumn 53, Issue 2, 2009, Pages 153-160

  Yoshida, Jin ^a   Tei, Genshin ^b   Mochizuki, Chie ^b   Masu, Yoshie ^b   Koda, Shigeki ^c   Kumagai, Shinji ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

Author keywords

Antineoplastic drugs; Biological monitoring; Closed system device; Hospital work environment; Surface contamination

Indexed keywords

ANTINEOPLASTIC DRUGS; BIOLOGICAL MONITORING; BIOLOGICAL SAFETY; CLOSED SYSTEM DEVICE; CLOSED SYSTEMS; CONVENTIONAL METHODS; DETECTION LIMITS; MANN-WHITNEY; MEDIAN CONCENTRATION; MIXING METHOD; SAMPLE COLLECTION; SAMPLING POINTS; SIGNED RANK; SURFACE CONTAMINATION; SURFACE CONTAMINATIONS; URINE SAMPLE; WORK ENVIRONMENTS; WORKING TABLE; HOSPITAL WORKS;

CONTAMINATION; EMPLOYMENT; HOSPITALS; HUMAN ENGINEERING; OCCUPATIONAL RISKS; STAINLESS STEEL; MIXING;

PULSE AMPLIFIERS; CONTAMINATION;

CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; BIOSAFETY; CONTAMINATION; CONTROLLED STUDY; DEVICE; GLOVE; HOSPITAL; HUMAN; INTERMETHOD COMPARISON; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; PHARMACIST; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; SAMPLING; URINALYSIS; WORK ENVIRONMENT; COMPARATIVE STUDY; ENVIRONMENTAL MONITORING; EQUIPMENT DESIGN; EVALUATION; HOSPITAL EQUIPMENT; METHODOLOGY; PROTECTIVE CLOTHING; URINE;

ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; ENVIRONMENTAL MONITORING; EQUIPMENT AND SUPPLIES, HOSPITAL; EQUIPMENT DESIGN; HUMANS; OCCUPATIONAL EXPOSURE; PHARMACISTS; PROTECTIVE CLOTHING; PROTECTIVE DEVICES;

EID: 65349140612     PISSN: 00034878     EISSN: 14753162     Source Type: Journal    
DOI: 10.1093/annhyg/men081     Document Type: Article

References (30)

1. Burgaz S, Karahalil B, Canhi Z et al. (2002) Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol; 21: 129-135
2. Carmel Pharma Japan. (2006) The package leaflet of Pha- Seal®. Tokyo, Japan: Carmel Pharma Japan.
3. Connor TH, McDiarmid MA. (2006) Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin; 56: 354-365
4. Connor TH, Anderson RW, Sessink PJ et al. (1999) Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm; 56: 1427-1432
5. Connor TH, Anderson RW, Sessink PJ et al. (2002) Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm; 59: 68-72.
6. Falck K, Grohn P, Sorsa M et al. (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet; 1: 1250-1251
7. Fujita H. (1986)Alkylating agents (section 2), pharmacokinetics of antineoplastic drugs. Osaka, Japan: Medical Review Co. Ltd.
8. Harrison BR, Peters BG, BingMR. (2006) Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm; 63: 1736-1744
9. Jakab MG, Major J, Tompa A. (2001) Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J Toxicol Environ Health A; 62: 307-318
10. Kitada M, Morikawa A, Katou H et al. (2005) The revised version of guideline of handling antineoplastic drugs in medical center-manual of handling antineoplastic drugs. Tokyo, Japan: Jiho Co.
11. Krstev S, Perunicic B, Vidakovic A. (2003) Work practice and some adverse health effects in nurses handling antineoplastic drugs. Med Lav; 94: 432-439
12. Massoomi FF, Neff B, Pick A et al. (2008) Implementation of a safety program for handling hazardous drugs in a community hospital. Am J Health Syst Pharm; 65: 861-865
13. National Institute for Occupational Safety and Health (NIOSH). (2004) NIOSH ALERT preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. Cincinnati, OH: NIOSH; pp. 1-61.
14. Nygren O, Gustavsson B, Ström L et al. (2002) Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit; 4: 739-742
15. Sasaki M, Dakeishi M, Hoshi S et al. (2008) Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay. J Occup Health; 50: 7-12.
16. Sessink PJ, Ryden N. (1999) Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm; 34: 1311-1317
17. Sessink PJ, Anzion RB, Van den Broek PH et al. (1992a) Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci; 14: 16-22.
18. Sessink PJ, Boer KA, Scheefhals AP et al. (1992b) Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health; 64: 105-112
19. Sessink PJ, Scholtes MM, Anzion RB et al. (1993) Determination of cyclophosphamide in urine by gas chromatographymass spectrometry. J Chromatogr; 616: 333-337
20. Sessink PJ, Kroese ED, van Kranen HJ et al. (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health; 67: 317-323
21. Sessink PJ,Wittenhorst BC, Anzion RB et al. (1997) Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health; 522: 240-244
22. Shirato S. (1992) Problems of cytotoxicity drug mainly based on antineoplastic tumor medicine. J Jpn Med Waste Res; 5: 1-32.
23. Spivey S, Connor TH. (2003) Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hospital Pharmacy; 38: 135-139
24. Thiringer G, Granung G, Holmen A et al. (1991) Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health; 17: 133-138
25. Undeger U, Basaran N, Kars A et al. (1999) Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat Res; 439: 277-285
26. Valanis B, Vollmer WM, Steele P. (1999) Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med; 1: 632-638
27. Vandenbroucke J, Robays H. (2001) How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice; 6: 146-152
28. Wick C, SlawsonMH,Jorgenson JAet al. (2003) Using a closedsystem protective device to reduce personnel exposure to antineoplastic agent. Am J Health Syst Pharm; 60: 2314-2320
29. Yoshida J, Kosaka H, Tomioka K et al. (2006) Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J Occup Health; 48: 517-522
30. Yoshida J, Kosaka H, Nishida S et al. (2008) Actual conditions of the mixing of antineoplastic drugs for injection in hospitals in Osaka Prefecture, Japan. J Occup Health; 50: 86-91.